Streetbeat News

Price Targets

CAPR

HC Wainwright & Co. has reiterated its Buy rating for Capricor Therapeutics, maintaining a price target of $40. This suggests confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 2:08 pm

SNOW

UBS analyst Karl Keirstead maintains a Neutral rating on Snowflake (NYSE:SNOW) and lowers the price target from $155 to $125.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 2:07 pm

PEG

UBS analyst Ross Fowler maintains a Neutral rating on Public Service Enterprise (NYSE:PEG) but raises the price target from $87 to $94.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 2:05 pm

CEG

UBS analyst Ross Fowler has maintained a Buy rating on Constellation Energy (NASDAQ:CEG) and raised the price target from $230 to $307.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 2:01 pm

DBVT

JMP Securities analyst Jonathan Wolleben has reiterated a Market Outperform rating for DBV Technologies (NASDAQ:DBVT) and maintained a $5 price target.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:58 pm

REGN

Regeneron Pharmaceuticals shares declined following a downgrade by Leerink Partners from Outperform to Market Perform, with a reduced price target from $1175 to $1077.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

CRWD

JMP Securities analyst Trevor Walsh has reiterated a Market Outperform rating for CrowdStrike Holdings (NASDAQ:CRWD) and maintained a $400 price target.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

ACN

JP Morgan analyst Tien-Tsin Huang maintains an Overweight rating on Accenture (NYSE:ACN) but lowers the price target from $376 to $370.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

ETSY

Truist Securities has reiterated its Buy rating on Etsy, maintaining a price target of $76. Analyst Youssef Squali continues to show confidence in the company's stock.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:55 pm

REPL

JP Morgan analyst Anupam Rama has maintained an Overweight rating on Replimune Group and raised the price target from $14 to $17.

Portfolio Pulse from Benzinga Newsdesk

September 24, 2024 | 1:54 pm